Agios Pharmaceuticals, Inc.

AGIO · NASDAQ

Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.

Follow Add to Watchlist Ask Question

NASDAQ AGIO Coverage Bootstrap Rare Disease Biopharma Hematology

Latest ReportMay 14, 2026AGIO: the billion-dollar cushion still needs AQVESME proofView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.